Avidity Biosciences to Participate in Upcoming Investor Conference

Rhea-AI Summary

Avidity Biosciences (Nasdaq: RNA), a biopharmaceutical company focused on developing Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in the upcoming Bank of America Securities 2025 Health Care Conference. The company's management will engage in a fireside chat scheduled for Tuesday, May 13, 2025, at 3:00 p.m. PT / 6:00 p.m. ET. Investors can access the live webcast and replay of the presentation through Avidity's investor relations website.

SAN DIEGO, May 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference:

• Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 3:00 p.m. PT / 6:00 p.m. ET

Live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.

About Avidity 
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.

Investor Contact:
Kat Lange
(619) 837-5014
investors@aviditybio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conference-302446201.html

SOURCE Avidity Biosciences, Inc.

FAQ

When is Avidity Biosciences (RNA) presenting at the Bank of America Securities Healthcare Conference 2025?

Avidity Biosciences will present at the Bank of America Securities Healthcare Conference on Tuesday, May 13, 2025, at 3:00 p.m. PT / 6:00 p.m. ET.

Where can I watch Avidity Biosciences' (RNA) Bank of America Securities conference presentation?

The presentation can be accessed through the 'Events and Presentations' page in the 'Investors' section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.

What type of therapeutics does Avidity Biosciences (RNA) develop?

Avidity Biosciences develops a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™).

What is the stock symbol for Avidity Biosciences?

Avidity Biosciences trades on the Nasdaq under the symbol RNA.